LUNG (Pulmonx Corporation) Stock Financials & Earnings

LUNGPulmonx Corporation

Mkt Cap$75M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$90M

Net Income (TTM)-$54M

EPS (TTM)-$1.33

Free Cash Flow (TTM)-$33M

Gross Margin74.2%

Op. Margin-59.3%

Net Margin-59.7%

FCF Margin-36.0%

P/S Ratio (TTM)0.8x

P/E Ratio (TTM)—

YoY Rev Growth+8.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$15M	$11M	-$16M
Q2 23	$17M	$13M	-$16M
Q3 23	$18M	$13M	-$15M
Q4 23	$19M	$14M	-$14M
Q1 24	$19M	$14M	-$15M
Q2 24	$21M	$15M	-$16M
Q3 24	$20M	$15M	-$14M
Q4 24	$24M	$18M	-$13M
Q1 25	$23M	$16M	-$15M
Q2 25	$24M	$17M	-$15M
Q3 25	$22M	$16M	-$14M
Q4 25	$23M	$18M	-$10M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$4M	—	—	$23M
Q2 23	$6M	—	—	$23M
Q3 23	$4M	—	—	$24M
Q4 23	$4M	$20M	$5M	—
Q1 24	$4M	—	—	$24M
Q2 24	$6M	—	—	$25M
Q3 24	$4M	—	—	$25M
Q4 24	$4M	$19M	$8M	—
Q1 25	$5M	—	—	$26M
Q2 25	$5M	—	—	$27M
Q3 25	$5M	—	—	$26M
Q4 25	$5M	—	—	$23M

Revenue by Geography

Quarter	Asia Pacific	Emea	Other International Geographical Areas	United States
Q1 23	$596K	$5M	$71K	$9M
Q2 23	$792K	$5M	$68K	$11M
Q3 23	$814K	$5M	$164K	$12M
Q4 23	$821K	$5M	$96K	$14M
Q1 24	$698K	$5M	$171K	$13M
Q2 24	$802K	$6M	$139K	$14M
Q3 24	$1M	$5M	$145K	$14M
Q4 24	$2M	$6M	$101K	$16M
Q1 25	$3M	$5M	$38K	$14M
Q2 25	$2M	$7M	$102K	$15M
Q3 25	$842K	$7M	$68K	$14M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$111M	$42M	$153M
Q2 23	$102M	$34M	$136M
Q3 23	$95M	$22M	$117M
Q4 23	$84M	$34M	$117M
Q1 24	$70M	$46M	$116M
Q2 24	$63M	$51M	$115M
Q3 24	$63M	$44M	$108M
Q4 24	$71M	$31M	$101M
Q1 25	$75M	$14M	$89M
Q2 25	$75M	$9M	$84M
Q3 25	$77M	$0	$77M
Q4 25	$70M	$0	$70M

Shares Outstanding

Revenue Per Employee

Revenue / Employee